source
- MapLight Therapeutics' mid-stage schizophrenia trial shows modest improvement but shares plunge two-thirdsMapLight Therapeutics announced that its experimental schizophrenia drug met its primary endpoint in a mid-stage study, delivering an average 4.5‑point reduction on the PANSS symptom scale after fi…
- Claris Bio raises $118M Series B and appoints new CEO to advance eye-drug for limbal stem cell deficiencyClaris Bio, a New Jersey biotechnology company, announced a $118 million Series B financing round co-led by Samsara BioCapital and Catalio Capital Management, with participation from Sofinnova Inve…